US › Healthcare

RenovoRx Inc (RNXT)

US · Healthcare · Biotechnology

$1.14-4.20%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$909,000

Revenue YoY

+115.4%

Net profit

$-2.9M

EPS

$-0.05

EPS estimate

$-0.08

Net margin

-320.2%

EPS came in at -0.05 against a street estimate of -0.08 — a beat of 37.5%.

Key statistics

Market cap

$51.4M

Forward P/E

0.0

P/B

8.19

Book value

$0.20

EPS (TTM)

$-0.31

52-week high

$2.59

52-week low

$0.70

50-day MA

$1.54

200-day MA

$1.09

Beta

0.97

Analyst view

Analysts rate RenovoRx Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $7.12.

Shareholding

Insiders

3.60%

Institutions

20.38%

Largest institutional holders

Fund	Stake
AIGH Capital Management, LLC	9.76%
Bleichroeder LP	3.69%
Vanguard Capital Management, LLC	3.20%
Geode Capital Management, LLC	0.94%
Sontag Advisory LLC	0.56%
Vanguard Fiduciary Trust Co	0.53%
Citadel Advisors Llc	0.30%
Chicago Partners Investment Group LLC	0.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for RenovoRx Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.